FDA Brief

Warning letters Devices

FDA warning letter to

O.N. Diagnostics, LLC

High riskIssued Sep 1Posted Oct 6Center for Devices and Radiological Health

FDA says O.N. Diagnostics sold changed VirtuOst VFA software without required clearance and had quality and reporting failures.

What happened

FDA inspected O.N. Diagnostics in Berkley, CA, from March 12-17, 2026. It found that VirtuOst VFA 3.0.0 had significant software changes—including a new machine learning algorithm, web-based architecture, and platform migration—without a new premarket notification, and it found CAPA, purchasing-control, and MDR procedure problems.

What FDA found

  1. VirtuOst VFA 3.0.0 was marketed without an approved premarket approval (PMA) or investigational device exemption (IDE), and significant changes were made without a new 510(k) premarket notification.

    21 U.S.C. § 351(f)(1)(B); 21 U.S.C. § 352(o); 21 U.S.C. § 360(k); 21 CFR 807.81(a)(3)(i)
  2. The corrective and preventive action (CAPA) procedure did not ensure needed corrective actions were taken without undue delay or that effectiveness was verified after implementation.

    ISO 13485:2016 Clause 8.5.2
  3. The CAPA procedure did not clearly define when to open a CAPA based on risk, and changes to it were not evaluated before implementation.

    ISO 13485:2016 Clause 8.5.2
  4. The purchasing controls procedure was vague about when and how suppliers would be monitored, trended, and re-evaluated.

    ISO 13485:2016 Clause 7.4.1
  5. The Medical Device Reporting (MDR) procedure lacked required definitions and did not correctly define serious injury, which could lead to wrong reportability decisions.

    21 CFR 803.17(a)(1)
  6. The MDR procedure lacked instructions for electronic reporting and complete Form FDA 3500A information, and an event file did not document the reportability decision process.

    21 CFR 803.17(a)(3); 21 CFR 803.18(b)(1)(i)

What FDA wants

FDA tells O.N. Diagnostics to stop activities that cause misbranding or adulteration of VirtuOst VFA 3.0.0, such as commercial distribution for the discussed uses. FDA asks for a written response within 15 business days with corrections, corrective actions, and a timetable.

Who should pay attention

  • makers of cleared medical device software
  • quality teams that manage CAPA and supplier monitoring
  • device firms that handle MDR reporting

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  2. Pro-Optics, LLC

    FDA warned Pro-Optics about unapproved material and color changes to contact lens cases and quality system failures.

    Medium
  3. Tides Medical LLC

    FDA warns Tides Medical over APLICOR 3D wound device sold without approval, exemption, or required FDA notice.

    High risk
  4. Advance-Esthetic LLC

    FDA says Advance-Esthetic markets three Zemits body-contouring devices without the required FDA clearance or approval.

    Medium